Haematologica 2016-12-01
Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial.
Related Questions
At what point is the neuropathy a contraindication to further bortezomib therapy?
New answer by Medical Oncologist at Winship Cancer Institute of Emory University (March 21, 2017)
Bortezomib and thalidomide cause the bulk of the neuropathy in myeloma patients worldwide, although thalidomide is rarely used in the U.S. because of more effective immune mod...